-
| Exchange | PINK |
|---|---|
| CurrencyCode | USD |
| ISIN | US20037C1080 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 682K |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.04 |
| Dividend Yield | None |
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CMRA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026